semaglutide alcohol craving A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used for weight loss, such as semaglutide, may also help reduce heavy drinking in individuals Heavy drinking: Semaglutide drugs linked

Historical Stock Returns for Natco Pharma More News on Natco Pharma Earnings Corporate Actions Stocks Get More Market Insights with 1 Year Returns:-7.48% Trending News Take your Analysis to Next Level with ScanX Access 50+ Readymade Screeners Use 200+ Custom Filters Get Full Market Insights Today's Top Gainers Today's Top Losers Global Indices FTSE 10600.37 (+0.27%) Hang Seng 24562.24 (-1.78%) DAX 24826 (-0.21%) CAC 8338.81 (-0.47%) US Tech 100 25530.979 (-1.44%) SSE Composite Index 3764.1548 (-3.05%) NIKKEI 225 64141.12 (-4.03%) TAIEX 42671.27 (-6.47%) US 30 52167.42 (-0.77%) KOSPI 6820.6 (-6.37%) S&P 7509.75 (-1.05%)

Build a supportive environment: Engage friends, family, or support groups to encourage your healthy habits

Foundayo (Orforglipron): An oral medication with the convenience of no special storage requirements, ideal for those seeking a straightforward daily option

The company also defended the safety of its active pharmaceutical ingredients, stating: "The APIs used to compound our Semaglutide and Tirzepitide (S&T) are sourced from reputable, internationally approved pharmaceutical manufacturers and have been tested in independent analytical laboratories for sterility and quality." In a striking claim, iDexis insisted it had dispensed its compounded product to over 200,000 patients without incident, writing: "To date we have dispensed our S&T compounded peptide product to 214 406 patients on prescription of their treating clinicians through the practices of their clinicians, or retail pharmacies of choice, without any reports of adverse reactions or conditions, only reports of great success and gratitude being expressed." iDexis went further, accusing SAHPRA of attempting to improperly influence the outcome of an ongoing court case: "We are of the opinion that the impugned findings of SAHPRA are nothing other than unsophisticated attempts orchestrated to improperly influence the outcome of the court case, especially in the light of the official investigation by SAHPRA launched in 2025 into the desirability of compounding peptides, in respect of which SAHPRA has not published any findings to date." The matter is scheduled to be heard in the Gauteng High Court in Pretoria on June 10 and 11, 2026

Focus on equity : Make sure all communities are benefiting by tracking outcomes by race, income, and locationand step in when gaps show up

The interest in adipose tissue has increased in recent years because of the rise in global rates of obesity and associated comorbidities [1]